Hydrolysis Levels in Infant Formula — Partial, Extensive, and Amino-Acid — The Infant Formula Atlas

By María López Botín · Mother of 2, researching infant formula and infant nutrition since 2018

This site provides research and comparisons, not medical advice. Consult your pediatrician before changing your baby's formula.

Hydrolyzed infant formula isn't one product category — it's a spectrum ranging from formulas with mildly broken-down proteins (marketed as "gentle" or "comfort") through extensively broken-down formulas for clinical CMPA management, all the way to amino-acid formulas where no intact protein remains. Each level has specific clinical applications and limitations, and using the wrong level for a given clinical situation is one of the most common errors in pediatric formula management.

Hydrolyzed formulas exist on a 4-tier spectrum: (1) intact-protein standard formulas — most cow-milk-based formulas; (2) partially hydrolyzed "HA" / "Gentle" / "Comfort" — peptides 5,000-15,000 Da, useful for general sensitivity but NOT adequate for CMPA; (3) extensively hydrolyzed (eHF) — Nutramigen, Alimentum, Gerber Extensive HA — peptides under 1,500 Da, adequate for ~90% of CMPA; (4) amino-acid (AAF) — PurAmino, EleCare, Neocate, Alfamino — no peptides, just free amino acids, for severe CMPA, FPIES, EoE. Per AAP + NASPGHAN guidance, hydrolyzed formula choice should match the specific clinical indication; HA formulas are NOT a substitute for eHF in CMPA.

The hydrolysis spectrum

Hydrolysis breaks intact proteins into smaller peptides via enzymatic digestion. The degree of hydrolysis determines the size of resulting peptides, which determines whether the immune system recognizes them as allergenic.

Tier 1 — Intact protein standard formulas. Cow milk proteins (caseins, β-lactoglobulin, α-lactalbumin) are intact. Most cow-milk-based formulas: Similac, Enfamil, Bobbie, ByHeart, HiPP, Holle, Kendamil, Earth's Best. Intact proteins can trigger CMPA reactions in sensitized infants.

Tier 2 — Partially hydrolyzed (PHF / HA / Comfort / Gentle). Proteins broken into peptides ranging 5,000-15,000 Da (still large fragments). HiPP HA, Enfamil Gentlease, Similac Total Comfort, Similac Sensitive, Gerber Good Start GentlePro. The hydrolysis is enough to ease general digestion but not enough to prevent CMPA reactions in most cases.

Tier 3 — Extensively hydrolyzed (eHF). Proteins broken into peptides under 1,500 Da (smaller than most CMPA-triggering epitopes). Nutramigen (with Enflora LGG probiotic), Alimentum, Gerber Extensive HA, Pregestimil. Adequate for approximately 90% of CMPA infants.

Tier 4 — Amino-acid (elemental, AAF). No peptides — protein replaced entirely by free amino acids. PurAmino, EleCare, Neocate, Alfamino. Adequate for virtually 100% of CMPA infants and the standard for severe cases (FPIES, EoE, multiple food allergies).

Per the PubMed extensively hydrolyzed and amino-acid formula clinical literature, the response rates above are consistent across multiple clinical trials and form the basis for current AAP and NASPGHAN recommendations.

Why the marketing creates confusion

Per AAP formula-feeding guidance, the "HA" or "Hypoallergenic" labeling on partially hydrolyzed formulas is problematic because:

"HA" historically suggested allergy management but partially hydrolyzed formulas don't manage active allergy adequately
FDA labeling rules distinguish "Hypoallergenic" labeled products (which require demonstrated efficacy in 90% of CMPA infants per FDA standards) from "HA" or "for sensitive stomachs" products (which don't require this level of demonstrated efficacy)
Marketing of "gentle" or "comfort" implies digestive easing but doesn't reliably treat CMPA

Result: a parent reading "HA" or "Hypoallergenic" or "for sensitive tummies" on a label may reasonably assume the product addresses CMPA when it doesn't. The prescription-grade Nutramigen, Alimentum, PurAmino, EleCare, Neocate are the products meeting FDA Hypoallergenic standard.

Clinical applications by tier

Standard intact-protein formulas: appropriate for typical healthy infants without specific clinical indications. The specifics below follow the site's primary-source methodology and reflect the editorial judgement applied across every comparable record in the Atlas.

Partially hydrolyzed formulas (PHF): appropriate for:

General digestive sensitivity (gas, fussiness, mild reflux)
Atopy prevention in low-risk infants (some evidence; not for active allergy management)
Family preference for slightly broken-down protein

NOT appropriate for: confirmed CMPA, FPIES, EoE, severe atopic dermatitis with food-protein involvement.

Extensively hydrolyzed formulas (eHF): appropriate for:

Confirmed CMPA — first-line option per AAP and NASPGHAN
Atopic dermatitis with documented food-protein involvement
Mild FPIES (some cases respond to eHF)
Specific transition planning for non-CMPA infants with food-protein sensitivity

NOT appropriate for: severe FPIES, EoE, multiple food allergies, eHF non- responders.

Amino-acid formulas (AAF): appropriate for:

eHF non-responders in CMPA (~10% of CMPA infants)
Confirmed FPIES, particularly multiple-food FPIES
EoE (first-line dietary intervention per NASPGHAN)
Multiple food allergies
Short bowel syndrome and other malabsorption conditions
Severe atopic dermatitis with documented multiple food triggers

The cost progression is steep: standard formula is least expensive, AAF is most expensive (often 5-10× standard). Insurance coverage for hypoallergenic formula varies; with appropriate diagnostic documentation, eHF and AAF are typically covered for documented CMPA, FPIES, and EoE.

How hydrolysis is achieved

Hydrolyzed formulas are produced by enzymatic digestion of cow's milk proteins:

Casein hydrolysates — break casein proteins; e.g., Nutramigen (extensively hydrolyzed casein) and Alimentum (extensively hydrolyzed casein-based)
Whey hydrolysates — break whey proteins; e.g., Pregestimil (eHF with whey component), some HA formulas
Mixed hydrolysates — combinations of casein and whey

Per NASPGHAN clinical guidance, the source protein doesn't matter clinically as much as the degree of hydrolysis. An extensively hydrolyzed casein formula and an extensively hydrolyzed whey formula have similar CMPA management efficacy when both achieve adequate peptide-size reduction.

The taste reality

Hydrolyzed formulas taste different — and meaningfully worse to most infants — than standard formulas. The bitter, somewhat unpleasant taste of extensively hydrolyzed and amino-acid formulas comes from the free amino acid composition (some amino acids taste bitter on their own, more intensely without the masking effect of intact proteins).

This affects clinical management:

Infants transitioning from standard formula to eHF or AAF often refuse the new formula for several days
Families benefit from gradual transition (mixing increasing proportions of eHF/AAF with familiar formula over a week)
Once tolerated, the taste preference adapts — long-term feeding is generally accepted

For severe CMPA where AAF is medically necessary, taste preference doesn't override clinical need; transition support helps.

Goat milk hydrolysates — emerging category

A small but growing category is goat-milk-based extensively hydrolyzed formulas (some specialty brands in EU markets, limited US availability). The clinical position: for the majority of CMPA infants, cow-milk-based eHF works regardless of the protein source, because the hydrolysis is what matters. Goat-milk hydrolysates might be useful for the rare infant who has both CMPA and tolerates goat protein (unusual, given high cross- reactivity), but standard cow-milk eHF is the well-evidenced first-line.

What families should know

Don't conflate "gentle" and "hypoallergenic." Marketing language varies; the FDA's Hypoallergenic-label standard requires extensively hydrolyzed or amino-acid formula. "Gentle," "Comfort," and "Sensitive" labels are typically partially hydrolyzed and don't meet the same standard.

Don't choose hydrolyzed formula without clinical indication. These formulas taste worse, cost more, and aren't necessary for typical infants. Pediatric or pediatric allergy guidance directs the appropriate level.

Don't escalate hydrolysis level without documented inadequate response. The diagnostic pathway is sequential: standard formula → partially hydrolyzed for general sensitivity → eHF for CMPA → AAF for eHF non- responders or severe cases.

Do work with insurance for hypoallergenic formula coverage. With appropriate pediatric documentation of CMPA, FPIES, or EoE, insurance typically covers eHF and AAF — making the cost difference manageable.

Do continue the hypoallergenic formula until pediatric guidance for re- challenge. Premature reintroduction can re-establish symptoms and prolong the management timeline.

Frequently asked questions

What's the difference between HA, gentle, and hypoallergenic formula?

These terms describe different levels of protein hydrolysis with very different clinical applications. 'HA' (Hypoallergenic-marketed) and 'Gentle' or 'Comfort' formulas are typically partially hydrolyzed — peptides remain at 5,000-15,000 Da, useful for general digestive sensitivity but NOT adequate for actual CMPA. True 'Hypoallergenic' per FDA labeling standard requires extensively hydrolyzed (peptides under 1,500 Da, e.g., Nutramigen, Alimentum) or amino-acid formula (no peptides, e.g., PurAmino, EleCare) — products demonstrated effective in 90% of CMPA infants. The marketing distinction matters: 'gentle' partially hydrolyzed formulas are general-comfort products; FDA-Hypoallergenic-labeled products are clinical CMPA management products. For confirmed CMPA, partially hydrolyzed formulas are inadequate and the prescription-grade extensively hydrolyzed or amino-acid formulas are required.

Which hydrolyzed formula should I try first if my baby might have CMPA?

Per AAP and NASPGHAN guidance, the standard first-line option is extensively hydrolyzed formula (eHF) — Nutramigen (with Enflora LGG probiotic), Alimentum, Gerber Extensive HA, or Pregestimil. The trial duration is 2-4 weeks under pediatric supervision; approximately 90% of CMPA infants improve substantially in this window. If the eHF trial doesn't produce adequate improvement after 4 weeks, escalation to amino-acid formula (PurAmino, EleCare, Neocate, Alfamino) is the next step — covering the remaining 10% of CMPA infants who don't tolerate eHF. Don't start with partially hydrolyzed 'HA' or 'Gentle' formulas for suspected CMPA — they're not adequate. Don't start with goat milk or soy formulas — cross-reactivity is too high. Pediatric or pediatric allergy guidance coordinates the trial protocol and confirms the diagnosis via reintroduction challenge once symptoms resolve.

Why does extensively hydrolyzed formula taste different?

The hydrolysis process breaks proteins into smaller peptides and free amino acids. Intact proteins are largely tasteless; many free amino acids taste bitter (particularly leucine, isoleucine, valine, methionine, tryptophan). When the masking effect of intact proteins is removed, the bitter flavors become more apparent. Amino-acid formulas (PurAmino, EleCare, Neocate, Alfamino) have an even more pronounced bitter taste because they're entirely free amino acids. The taste difference is significant enough that infants transitioning from standard formula often refuse the new formula initially. Most infants adapt over 5-7 days, particularly with gradual transition mixing increasing proportions of the new formula with the familiar one. For severe CMPA where the formula is medically necessary, taste tolerance develops with persistence — but it's a real adjustment for the family.

Is partially hydrolyzed formula better than regular formula for sensitive babies?

Sometimes, with caveats. Partially hydrolyzed formulas (HiPP HA, Enfamil Gentlease, Similac Total Comfort, Similac Sensitive, Gerber Good Start GentlePro) may help some non-CMPA infants with general digestive sensitivity, gas, or mild fussiness. The smaller peptides may digest somewhat more easily than intact proteins. However: (1) the evidence for partially hydrolyzed formulas as superior to standard formulas in non-CMPA contexts is mixed, (2) they cost more than standard formulas, (3) they're NOT adequate for actual CMPA. For families with infants showing general fussiness without specific CMPA signs, optimization of feeding (volume, schedule, position) often resolves the issue without changing formula. If formula change is desired, the partially hydrolyzed option is reasonable but should be tried as a 2-week trial rather than indefinitely without clinical improvement. For atopy prevention in low-risk infants, recent evidence suggests partially hydrolyzed formula may have modest benefit; AAP guidance is cautiously supportive.

How do I know if my baby needs amino-acid formula instead of extensively hydrolyzed?

Pediatric specialty input drives this decision. Indications for amino-acid formula (PurAmino, EleCare, Neocate, Alfamino) instead of or after extensively hydrolyzed formula: (1) inadequate response to 4-week eHF trial in CMPA — symptoms persist after eHF transition; (2) confirmed FPIES, particularly multiple-food FPIES; (3) confirmed eosinophilic esophagitis (EoE); (4) multiple food allergies; (5) short bowel syndrome and other severe malabsorption; (6) severe atopic dermatitis with documented multiple food protein triggers. The progression from eHF to amino-acid formula isn't automatic — pediatric allergy or pediatric gastroenterology evaluates the specific case before escalating. Cost considerations matter: amino-acid formula is significantly more expensive than eHF, but with appropriate diagnostic documentation, insurance typically covers it for documented indications. Self-escalation from eHF to amino-acid formula without clinical guidance isn't recommended.

Can I use hydrolyzed formula for general 'gas and fussiness' even without confirmed CMPA?

Sometimes reasonable as a structured trial; not recommended as default. For infants with persistent general digestive sensitivity (gas, fussiness, mild reflux) without specific CMPA signs, a 2-week trial of partially hydrolyzed formula (HA / Gentle / Comfort line) under pediatric guidance is defensible — it may resolve some general sensitivity patterns without committing to expensive extensively hydrolyzed formula. If the partial-hydrolysis trial helps, continue. If not, the issue likely isn't food-protein-driven and other interventions (paced feeding, position changes, volume optimization) are higher-yield. Don't start extensively hydrolyzed or amino-acid formula without specific clinical indication — these are designated for documented CMPA, FPIES, or EoE, and their cost and taste challenges aren't justified for general sensitivity. Pediatric coordination is the right approach for any persistent feeding issue beyond normal infant variation.

Will hypoallergenic formula prevent my baby from developing food allergies?

Modest evidence for partial hydrolysates in atopy prevention; not a guarantee. Per AAP and NIAID food allergy research, partially hydrolyzed formulas (HA / Comfort) given to high-atopy-risk infants in the first 4-6 months may modestly reduce risk of developing atopic dermatitis and possibly food allergies in early childhood — the evidence is suggestive but not definitive. Extensively hydrolyzed and amino-acid formulas are designed for active allergy management, not prevention, and aren't recommended as preventive measures in low-risk infants. The most evidence-supported atopy prevention strategy is exclusive breastfeeding for the first 4-6 months when feasible. For infants who can't be breastfed, partially hydrolyzed formula may have modest preventive benefit in high-risk families (parents with confirmed atopic disease) — but this is a topic that benefits from pediatric or pediatric allergy guidance rather than a default decision. The general public health framing: don't use hypoallergenic formulas preventively without specific clinical indication.